Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Express Scripts
Moodys
Harvard Business School

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Patent: 9,775,915

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,775,915
Title:Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L.sup.1-(A-L.sup.2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L.sup.1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L.sup.2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment. ##STR00001##
Inventor(s): Myers; Andrew G. (Boston, MA), Smaltz; Daniel J. (Cambridge, MA), Schumacher; Andreas (Bottmingen, CH)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Application Number:14/647,198
Patent Claims:see list of patent claims

Details for Patent 9,775,915

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial President and Fellows of Harvard College (Cambridge, MA) 2032-11-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Mallinckrodt
AstraZeneca
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.